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CHAPTER 
A comparative screen of the 
human HSPB family of molecular 
chaperones reveals HSPB7 as a 
superior suppressor of aggregation of 
polyglutamine containing proteins
Michel J Vos*, Marianne P Zijlstra* & Harm H Kampinga
Department of Cell Biology, Section of Radiation and Stress Cell Biology, University 







A small number of heat shock proteins have previously been shown to act protectively on ag-
gregation of several proteins containing an extended polyglutamine tract, which are linked to 
several neurodegenerative diseases. A specific subfamily of heat shock proteins is formed by 
the HSPB family of molecular chaperones, of which a few members are known to act as anti-
aggregation proteins in vitro. Furthermore, mutations in a subset of HSPB members are linked 
to neuropathies, underlining the importance of this subfamily in protein folding, aggregation and 
neurological diseases.  
Using overexpression, we screened the HSPB family for novel inhibitors of polyglutamine ag-
gregation and provide a comparative overview on the human HSPB family in view of preventing 
polyglutamine aggregation. This screen revealed several HSPB members as novel suppressors 
of polyglutamine aggregation, with HSPB7 as the most active one. 
Interestingly, this HSPB protein was found to function independently of the HSP70 machine 
and heat-shock respons. Furthermore, it did not target polyglutamine proteins for proteasomal 
degradation, but was found to depend in part on autophagy for its activity. Moreover, it prevented 
polyglutamine induced toxicity in cells and in an in vivo model for SCA3, showing the potential 
of HSPB7 as a potential therapeutic target. 
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Introduction
Several inherited neurodegenerative diseases exist which are based on a CAG triplet expan-
sion in the affected genes. This results in elongation of the glutamine (polyQ) tract present in 
the proteins where, in general, an extension beyond 35-40 glutamines causes disease whereby 
the age at onset is related to the length of the expansion (1). These diseases include amongst 
others polyQ extensions in the androgen receptor, the TATA-box binding protein, huntingtin and 
several ataxia-related genes (SCA genes). The corresponding diseases are characterized by 
protein misfolding and aggregate / inclusion formation of the affected proteins with a concurrent 
increase in proteotoxic stress. 
From (cellular) studies it has become clear that certain heat shock proteins, as molecular chap-
erones, form a potent natural defense against proteotoxic stress induced by these protein mis-
folding diseases. Heat shock proteins are divided into several main families which are both 
structurally and functionally highly divergent (2). Within the HSPH (Hsp110) , HSPA (Hsp70) and 
DNAJ (Hsp40) families, several members have been found that can reduce aggregation and 
toxicity associated with polyglutamine (polyQ) containing proteins and other misfolded proteins 
(3-10). Also within the mammalian small heat shock protein (HSPB) family, some members, 
in particularly HSPB1 and HSPB8, have been reported to suppress toxicity or aggregation of 
neuropathy-causing mutated proteins (11;12). In cells, HSPB1 suppresses mutant huntingtin-
induced reactive oxygen species formation and cell death which is dependent on the phos-
phorylation status of HSPB1 (13). In a mouse model of Huntington disease (HD), however, 
HSPB1 overexpression did not improve the HD phenotype and furthermore it failed to form large 
HSPB1-substrate complexes which are implicated in chaperone activity (14). HSPB8 acts via 
another mechanism and modulates toxicity of HD via the induction of autophagy and a trans-
lational shut-down (15;16). Whether or not HSPB8 can also rescue HD pathology in vivo is yet 
unknown. Furthermore, the potency of the other HSPB members in reducing proteotoxic stress 
remains unknown. 
The human HSPB family consists of eleven members and the amino acid sequence variation 
between members of this family is larger than in any of the other HSP families. Here, we present 
a systematic comparison of ten members of the human HSPB family for their ability to modulate 
either HD or SCA3 aggregation or assist in the refolding of a heat-denatured substrate. The 
effectiveness to prevent aggregation largely differed between members and, in part, was de-
pendent on the type of the misfolded substrate. However, within the HSPB family, HSPB7 was 
overall the most potent suppressors of HD and SCA3 aggregation. In addition, HSPB7 was able 
to reduce polyQ related toxicity in cells and protected against polyQ-related eye-degeneration 
in a Drosophila SCA3 model. In contrast to e.g. HSPB1, HSPB7 is not a classical chaperone 
since it is unable to assist in refolding of heat denatured proteins. In addition, it does not depend 
on the HSPA chaperone machine for its anti-aggregation activity. Although its precise mode of 




Chemicals were obtained from Sigma, beetle luciferin from Promega. Antibodies against the V5 
tag (Invitrogen), EGFP (JL-8) (BD bioscience), GAPDH (6C5) (RDI research diagnostics), HA 
tag (Covance), HSPB7 (Abcam) and HSPA1A (SPA-800), HSPA6 (SPA-754) from Stressgen 
were mouse monoclonal. The antibodies against DNAJB1 (SPA-400) (Stressgen) and HSPB5 
(Abcam) were rabbit-polyclonal. Reagents for Western blotting were obtained from Amersham. 
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Secondary antibodies for immunocytochemistry used were CY5 anti-mouse and FITC anti-
mouse (Jackson) and CY3 anti-mouse (Amersham). 
Molecular techniques
Standard recombinant DNA techniques were carried out essentially as described by Sambrook 
et al. Oligonucleotide primers (Biolegio). Restriction enzymes and DNA polymerases were used 
according to the manufacturer’s instructions (Invitrogen, New England Biolabs). DNA sequenc-
ing reactions were carried out by ServiceXS. 
Plasmid generation
The truncated SCA3 fragments were PCR amplified from skin fibroblasts from heterozygous 
SCA3 partient with 64 and 82 CAG-repeat present in the Ataxin3 gene and cloned into pCMV-
EGFP and pCDNA5.1-FRT/TO-EGFP respectively, in frame with EGFP. Plasmid containing ei-
ther HDQ43 or HDQ74 were kindly provided by Dr. David Rubinsztein (Cambridge, UK). Gen-
eration of the human HSPB plasmid library was described before as well as the HSPB7 deletion 
mutants (Chapter 3). For retroviral transduction, the pQCXIN vector (Clontech) was used for 
cloning. The Ub-R-EGFP construct was kindly provided by Dr. Dantuma (Karolinska Institutet, 
Sweden) The construct encoding His-BAG3 and HA-BAG1 have been described before (21;44). 
The construct encoding the dominant negative HSF-1 was kindly provided by Prof. dr. N.H. Lub-
sen (Nijmegen, the Netherlands). 
Cell lines, cell culture, transfections and transductions
NG108, mouse embryonic fibroblasts (MEF) and human embryonic kidney 293 cells expressing 
the tetracycline repressor (Flp-In T-Rex HEK293, Invitrogen) were grown in Dulbecco’s modi-
fied Eagle’s medium (Gibco) supplemented with 10% fetal calf serum (Griener Bio-one) at 37 
°C under a humidified atmosphere containing 5% CO2. The generation of HEK293-HDQ119, 
with integration of a tetracycline regulatable expression vector coding for EGFP-HDQ119, has 
been described before (Hageman et al. submitted elsewere). Gene expression in Flp-In T-Rex 
HEK293 cells was induced with a final concentration of 1 µg/mL tetracycline. HEK293 cells and 
MEF cells were transfected using Lipofectamine (Invitrogen) according to the manufacturer’s 
instructions using 1μg of plasmid DNA per 35-mm dish. NG108 cells were differentiated into 
neuronal-like cells by addition of 2 mL differentiation medium (DMEM containing 1 mM sodium 
pyruvate, 50 μM 3-Isobutyl-1-methylxanthine, 10 μM 5’-(N-Ethylcarboxamido)adenosine, 0,5% 
FCS) to 35000 cells in a 35mm dish. Seven days later, cells were transfected using Effectene 
(Qiagen) according to the manufacturer’s instructions using 0,6 μg of plasmid DNA per 35-mm 
dish. For transduction, retroviral particles were generated by co-transfection of HEK293-T cells 
with pCL-ampho and pQCXIN endoding either HSPB5 or HSPB7 using Fugene (Roche) accord-
ing to the manufacturers instructions. The supernatant was collected after 48 hours and filtered 
using a Millex-HV filter (Millipore). Cells were transduced by adding 1,5 mL of filtrated medium 
containing 4 µg/mL polybrene. Medium was replaced after 24 hours and transduced cells were 
selected using puromycin selection.
Drosophila
Fly stocks were maintained at 22°C according to standard protocols. GAL4 driver stocks 
were obtained from the Bloomington Stock Centre (Indiana University, USA). The GMR-UAS-
SCA3Q78 fly used for the eye-degeneration screen was generously provided by N. Bonini (Uni-
versity of Pennsylvania, USA) and maintained at 25 °C. HSPB7 transgenic lines were generated 
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by Genetic Services Inc. (Sudbury, USA) by injection of the pUAS transformation vector into the 
W1118 genetic background. 
Westernblot analysis
Samples were prepared in Laemmli sample buffer. Equal amount of protein were separated on 
10% or 12,5% SDS-PAGE gels followed by transfer onto nitrocellulose membranes. Primary an-
tibodies were used at the following dillutions: V5 (1:5000), EGFP (1:5000), GAPDH (1:10000), 
HSPA1A (1:5000), HSPA6 (1:5000), DNAJB1 (1:5000). After a one hour incubation with the pri-
mary antibody in PBS-Tween20, membranes were incubated with HRP-conjugated secondary 
antibodies at a 1:5000 dillution. Detection was performed using enhanced chemiluminescence. 
Filtertrap assay
The filtertrap assay was performed basically as described by Carra et al. (12). Briefly, cells 
grown in a 35mm dish were lysed in 200 μL FTA buffer (10 mM Tris-Cl pH 8.0, 150 mM NaCl, 
50 mM dithiothreitol) containing 2% SDS. 100 μL, 20 μL and 4 μL sample was applied onto a 
prewashed (FTA, 0,1% SDS) 0,2 μM cellulose acetate filter contained in a Bio-Dot microfiltration 
apparatus (Biorad). Gentle suction was applied to filtrate the samples followed by one washing 
step using FTA, 0,1% SDS. Trapped material was probed with anti-EGFP (GL-8) or anti-HA at a 
1:5000 and 1:2000 dillution respectively followed by incubation with HRP-conjugated secondary 
antibodies at a 1:5000 dillution. Detection was performed using enhanced chemiluminescence. 
Microscopy
For microscopy, cells were plated 24 hours before transfection. For fixation, the coverslips were 
washed with cold PBS and fixed for 15 minutes with methanol (-20o C). Cells were permeabilized 
in blocking solution (100 mM glycine, 3% BSA, 0,1% triton) for 1 hour followed by 1 hour incuba-
tion with the primary antibody (V5 anti-mouse, 1:200, SC-35 anti-mouse, 1:10000, MYC anti-
rabbit 1:200). After three washing steps, coverslips were incubated for 1h with CY3-conjugated 
anti-rabbit secondary antibody (Amersham Biosciences) at 1:200 dilution or with FITC-conju-
gated anti-mouse secondary antibody (Jackson) at 1:200 dilution. After three washing steps, 
the coverslips were mounted using Citifluor mounting medium (Citifluor Ltd). Images were ob-
tained using an inverted confocal laser scanning microscope (TCS SP2, DM RXE, Leica) with 
a 63×/1.32 NA oil objective. 
Luciferase refolding assay
Chaperone activity of HSPB members was assessed by using the luciferase refolding assay 
(41). Briefly, HEK293 cells were co-transfected with luciferase (NucSuperluc-EGFP) (59) to-
gether with HSPB encoding plasmids (1:9 ratio). Two hours after transfection, expression was 
induced by addition of tetracycline. After 24 hours, cells were resuspended and divided into 1 mL 
portions in tissue-grade 10 mL tubes. The following day, cells were given a heat-shock (30 min-
utes at 43o C) in the presence of cycloheximide (20 μg/mL) and 4-morpholinepropanesulfonic 
acid (MOPS; 20 mM, pH7.0) in order to inhibit protein synthesis and increase the buffer capacity 
of the medium respectively. After heat treatment, cells were allowed to recover before luciferase 
activity was determined (3 hours at 37 o C). Luciferase activity measurements were performed 
using a Berthold Lumat 9510 luminometer (Berthold Technologies). 
Sucrose gradient centrifugation
Cells from a 35mm dish were scaped in 200 μL cold lysis buffer (150 mM NaCl, 50 mM NaH2-
PO4, 10 mM imidazole, 0,5% NP-40, 1,5 mM MgCl2 and 3% glycerol, pH8). Cells were lysed 
by five passages through a 25 gauge needle, followed by centrifugation at 300G for 15 minutes. 
Chapter 4
62
The cell lysate was loaded on top of a 10-80% sucrose gradient (10 mM Tris-HCl, pH8, 5 mM 
EDTA, 50 mM NaCl) and centrifuged for 18 hours at 100000g using a Sorvall Discovery 90SE 
ultra centrifuge and the SW55 rotor. Fractions of 400 μL were precipitated by adding an equal 
volume of 25% (w/v) trichloroacatic acid. After a 30 minute incubation on ice, proteins were 
pelleted at 14000 rpm for 15 minutes. The pellet was washed twice with 80% acetone (-200C) 
and allowed to dry. The pellet was dissolved in 20 μL 0,1M NaOH containing 1% SDS. An equal 
amount of Laemmli buffer was added and samples were boiled for five minuten follwed by West-
ern blot analysis. 
Clonogenic assay
A clonogenic assay was used to determine cellular survival when overexpressing EGFP-
HDQ119 without or with HSPB members. Exponentially growing cells were plated in triplicate 
in 10 cm dishes at a density of 200 cells per dish. EGFP-HDQ119 expression was activated by 
addition of tetracycline. Cells were allowed to grow and form colonies for two weeks, after which 
they were fixed and stained (0,1% Coomassie Brilliant Blue, 50% methanol, 10% glacial acetic 
acid followed by washing (10% methanol, 7,5% glacial acetic acid). The effect of EGFP-HDQ119 
expression and co-expression of HSPB5 and HSPB7 was determined by comparing colony 
reduction in the presence of EGFP-HDQ119 expression. 
Proteasome inhibition, proteasome activity measurement and autophagy 
analysis
Proteasomal activity was blocked by addition of 10 μM MG132 to the culture medium for 12 
hours. Proteasomal activity was monitored by co-transfection of UB-R-EGFP followed by West-
ernblot- and FACS analysis. The role of autophagy in reducing polyQ aggregation was analysed 
using mouse embryonic fibroblasts lacking the ATG5 gene which was kindly provided by Dr. 
Mzushima, Okazaki, Japan. 
Results
HSPB7 is the most potent HSPB member in preventing polyglutamine ag-
gregation
Certain members of the HSPB family have been reported to suppress protein aggregation in 
vitro using several model proteins (17-21). Specific substrates include amongst others, amyloid 
beta (19), desmin filaments (20) and mutated huntingtin (21). Apart from these specific sub-
strates, HSPB proteins can bind to many other non-native proteins in general (22-24). In cell free 
systems, several HSPB members were shown to be rather generic in preventing aggregation 
of a number of unrelated proteins and support their refolding via interacting with the HSPA1A 
(HSP70) machine (25). In cells, HSPB proteins are found to interact with cytoskeletal elements 
but may also here act rather promiscuously in preventing protein aggregation and support pro-
tein refolding (26-28). 
To compare the effectiveness of the HSPB family in dealing with disease-related misfolded pro-
teins, we co-expressed them together with either mutant Huntingtin exon 1 (Htt) or a fragment 
of Ataxin-3 (SCA3), both containing an expanded glutamine tract. Using the filtertrap assay 
(29) to detect protein aggregates, we found that aggregation of a moderately expanded HD 
protein (HA-HttQ43) was strongly reduced by co-expression of four HSPB members (HSPB6, 
HSPB7, HSPB8, HSPB9), whereas HSPB1 and HSPB4 were only marginally effective (Figure 
1a). HSPB2, HSPB3, HSPB5 and HSPB10 showed no activity at all. Using a HD fragment con-
taining a longer polyQ tracts (EGFP-HttQ74), co-expression of HSPB7 and HSPB9 resulted in 
a considerable reduction of aggregated material, while co-expression of either HSPB1, HSPB4 




























































































































































































































































































Figure 1. The human HSPB family contains potent suppressors of polyQ expanded Huntingtin ag-
gregation. HEK293 cells were co-transfected with V5-tagged HSPB members and polyglutamine encoding 
plasmids at a 9:1 plasmid ratio. Cells were lysed after 24 or 48 hours and analysed by the filtertrap-binding 
assay using five-fold dillutions. Several HSPB members were able to suppress polyglutamine aggregation 
of a protein with (A) 43 glutamines; HA-HttQ43 (B) 74 glutamines; EGFP-HttQ74 and (C) 119 glutamines; 
EGFP-HttQ119. (D) To compare the effect of the V5-tag, also non-tagged HSPB members were co-ex-
pressed with the EGFP-HttQ74 encoding plasmid, (E-G) Expression levels of the polyglutamine proteins 





























































































Figure 2. The human HSPB family contains 
potent suppressors of polyQ expanded 
SCA3 aggregation. (A) HEK293 cells were 
co-transfected with V5-tagged HSPB members 
and truncated EGFP tagged SCA3 containing a 
stretch of 82 glutamines at a 9:1 plasmid ratio. 
After 24 hours cells were lysed and analyzed by 
the filtertrap-binding assay using five-fold dillu-
tions. (B) Expression levels of EGFP-SCA3-Q82 




or HSPB6 was less effective (Figure 1b). At a glutamine length of 119, only HSPB7 was still 
effective in reducing the amount of aggregated material, while HSPB9 showed only a marginal 
effect (Figure 1c). Repeating the screen with the non-tagged HSPB library and EGFP-HttQ74 
led to similar results, i.e. that HSPB9 and especially HSPB7 are the most potent suppressors of 
polyQ aggregation (Figure 1d), indicating that the V5 tag had not affected the function of most 
HSPB members. Under all conditions of overexpressed HSPB members, the expression levels 
of the soluble fraction of the various Huntingtin proteins was not largely affected (Figure 1 e-g) 
meaning that different substrate concentrations could not explain differences in effectiveness of 
the various HSPB members. The difference in aggregation suppressive function of the various 
HSPB members was also not due to differences in expression levels or higher stability of the 
HSPB proteins themselves; in fact, HSPB7 and HSPB9 expression levels were amongst the 
lowest of the whole HSPB family (Figure 1e,f). This means that their effectiveness may even be 
somewhat underestimated here. 
We next repeated the screen using another polyglutamine expanded protein, Ataxin-3 (EGFP-














































































Figure 3. HSPB7 can prevent polyglutamine aggregation in the cytosol and nucleus. (A) Confocal 
microscopy of HEK293 cells overexpressing cytosolic EGFP-HttQ74 (green signal) without or with co-ex-
pression of V5-HSPB7 for 48 hours. The nucleus was stained with DAPI (grey signal) (B) Expression lev-
els of V5-HSPB7 were modified by varying the amount of transfected plasmids while keeping the amount 
of EGFP-HttQ74 encoding plasmid constant. (C) Filtertrap-binding analysis shows a correlation between 
HSPB7 concentration and its effect on reducing polyglutamine aggregation. (D) Confocal microscopy of 
HEK293 cells overexpressing nuclear localized NLS-EGFP-HttQ74 (green signal) without or with co-expres-
sion of V5-HSPB7 for 48 hours. (E) Expression levels of V5-HSPB7 were modified by varying the amount 
of transfected plasmids while keeping NLS-EGFP-HttQ74 encoding plasmid constant. (F) Also for nuclear 
aggregation of polyglutamine proteins, a correlation exists between levels of HSPB7 and its activity in reduc-
ing aggregation of polyglutamine proteins. See Appendix 4 for colour print.
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suppressors; HSPB1, HSPB4 and HSPB8 also showed some, but minor activity (Figure 2a). In 
accordance with data from the HD screen (Figure 1e,f,g), HSPB effectiveness against aggrega-
tion was not accompanied by a detectable reduction in soluble SCA3Q82 levels (Figure 2b). 
HSPB7 activity is concentration dependent and active in the nucleus
Transient overexpression can often lead to non-physiologically high levels of expression per 
cell. Therefore, we titrated the levels of HSPB7 by varying the ratio between HSPB7 and polyQ 
expressing plasmids and analyzed the effects on suppression of polyQ aggregation. Exclu-
sively cytosolic inclusions were found when EGFP-HttQ74 was overexpressed (Figure 3a). 
This was markedly reduced when HSPB7 was co-expressed (Figure 3a). An increase in the 
HSPB7:EGFP-HttQ74 ratio (Figure 3b), was paralleled by a concurrent reduction in the extend 
of polyQ aggregation (Figure 3c). HSPB7 overexpression did not result in a reduction of soluble 
polyQ levels (Figure 3b), suggesting that rapid substrate degradation or translational inhibition 
are not the major pathways by which HSPB7 prevents aggregate formation. Next, we tested if 
HSPB7 could also prevent nuclear polyQ aggregation, a main feature of polyQ diseases related 
to cytotoxicity (4). Expression of a nuclear localization signal (NLS) containing EGFP-HttQ74 
construct shows the formation of solely nuclear aggregates (Figure 3d). Clearly, co-expression 
of HSPB7 also prevented aggregate formation in the nucleus (Figure 3d) in a concentration 
dependent manner (Figure 3e,f). Again, no large effects on soluble polyQ levels were observed 
(Figure 3e). 
HSPB7 does not target polyQ proteins for proteasomal degradation
Classical chaperone activity towards misfolded and non-foldable proteins is generally found to 
intertwine with cellular degradation pathways. Heat shock proteins such as HSPA1A, DNAJB1 
and DNAJB2 were shown to promote degradation of misfolded proteins through the ubiquitin-
proteasome system (30;31) while e.g. the Drosophila HSP40 member Mrj (ortholog of mamma-
lian DNAJB6/DNAJB8) and human HSPB8 were shown to induce autophagy (15;32). Although 
HSPB7 did not visibly reduce soluble HD or SCA3 levels (Figure 1f, 2b, 3b,e), part of the mis-
folded or aggregated substrate could specifically be targeted for degradation by either of these 
pathways. To test whether HSPB7 could promote proteasomal degradation we co-transfected 
cells with HSPB7 together with HA tagged HttQ43 and treated cells with the proteasome inhibi-
tor MG-132. Under such conditions, HSPB7 was still active in preventing aggregate formation 
(Figure 4a), whereas the protective action of DNAJB1, known to prevent polyQ aggregation by 
stimulating proteasomal degradation (30), was clearly reduced (Figure 4a). In addition, we used 
the proteasome activity reporter Ub-R-EGFP (33); when co-expressed together with DNAJB1 
the Ub-R-EGFP levels were strongly reduced, confirming the role of DNAJB1 in proteasomal 
degradation (Figure 4b). Co-expression of HSPB7, however, did not significantly affect the ex-
pression level of this proteasome activity reporter (Figure 4b). Co-expression of polyglutamine 
proteins (HA-HttQ43), that is sometimes suggested to negatively affect proteasomal activity 
(34), did not have an effect on proteasomal activity in our assays irrespective of chaperone co-
expression (Figure 4b). Analysis of Ub-R-EGFP levels by fluorescent-activated cell sorting gave 
comparable results (Figure 4c). DNAJB1 enhanced proteasomal degradation while HSPB7 did 
not. These data suggest that HSPB7 does not reduce polyQ aggregation by enhancing protea-
somal degradation.
 
HSPB7 is partly dependent on autophagic clearance of aggregated polyQ 
proteins
Although HSPB7 was also effective in the nucleus of cells, which would not support that it acts 
via autophagy, we decided to directly test the possibility that HSPB7 could prevent polyQ ag-
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gregation by stimulating autophagosomal clearance of misfolded proteins at least in the cytosol. 
Hereto, we co-expressed EGFP-HttQ74 with either HSPB7 or BAG3 in mouse embryonic fibrob-
lasts with or without a disruption of ATG5, a key regulator of autophagy (35). BAG3 was used 
as a positive control as it was shown that, in complex with HSPB8, it induces eIF2a phospho-
rylation and hereby reduced polyQ aggregation via protein synthesis inhibition and clearance 
of aggregates via autophagy (15;21). In cells positive for ATG5, polyQ aggregates are reduced 
when HSPB7 is co-expressed (Figure 5a) with no visible changes is soluble EGFP-HttQ74 lev-
els (Figure 5b) unlike overexpression of BAG3 
that also reduced polyQ aggregation in these 
ATG5 positive cells (Figure 5a), but with a con-
comittant large reduction in soluble EGFP-Ht-
tQ74 levels (Figure 5b). Cells lacking the ATG5 
gene show more polyQ aggregation in control 
conditions (Figure 5c), consistent with the role 
of constitutive autophagy in clearance of polyQ 
aggregates (36;37). As demonstrated before, 
BAG3 overexpression in ATG5 -/- cells was 
less effective in reducing polyQ aggregation 
than in ATG5 +/+ cells, although some activity 
remained, which can be attributed to its effect 
on protein synthesis leading to a large reduction 
of soluble EGFP-HttQ74 levels also in ATG5 -/- 
cells (Figure 5d) (16). In ATG5 -/- cells, HSPB7 
activity was largely reduced independent of an 
effect on soluble EGFP-HttQ74 levels (Figure 
5c, d). This suggests that, at least in the cy-
tosolic compartment, HSPB7 co-operates with 
autophagic mechanisms to reduce aggregated 
polyQ material but in a manner that is distinct 
from the BAG3/HSPB8 complex.
HSPB7 is not a classical chaperone
The canonical mechanism by which small heat 
shock proteins are believed to function is that 
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Figure 4. HSPB7 is not involved in proteasomal 
degradation. (A) HEK293 cells were co-transfected 
with V5-tagged DNAJB1 or HSPB7 together with HA-
HttQ43 at a 9:1 plasmid ratio. After 24 hour and 48 
hours, samples were generated and analysed by the 
filtertrap binding assay. In addition, cells were treated 
for 12 hours with the proteasome inhibitor MG132. 
(B) Co-transfection of V5-tagged DNAJB1 or HSPB7 
with the proteasomal activity reporter Ubr-EGFP, 
shows a reduction in Ubr-EGFP levels for DNAJB1 
co-expression, while HSPB7 does not influence Ubr-
EGFP clearance. Co-expression of HA-HttQ43 did 
not influence Ubr-EGFP clearance. (C) Fluorescent 
activated cell sorting measurements on Ubr-EGFP 
fluorescence levels show that DNAJB1, but not 
HSPB7, reduces the Ubr-EGFP fluorescence.
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namic de- and re-oligomerization steps, bind unfolded substrates that are subsequently trans-
ferred to HSPA protein machines for further processing (38;39). First, we tested whether HSPB7 
forms oligomers in cells, like the classical small HSPs, such as HSPB1 and HSPB5 do. Hereto 
we expressed V5-HSPB5 or V5-HSPB7 in HEK293 cells and separated the cell lysates on 
sucrose gradients. While HSPB5 was found throughout the gradients, indicating formation of 
oligomeric species of various sizes, HSPB7 was mainly localized at low density indicative of 
its existence as a mono- or dimeric species (Figure 6a). Native gel analysis confirmed these 
findings: V5-HSPB1 clearly migrated consistent with oligomeric species like V5-HSPB5, while 
V5-HSPB7 migrated mostly as a single molecular species (Figure 6b). So, in living cells HSPB7 
does not seem to form the canonical large HSPB oligomers.
To test whether, despite its non-classical characteristic, HSPB7 still could act as a classical 
chaperone, we used heat-denatured firefly luciferase as a model substrate (40-42). Cells ex-
pressing luciferase with or without co-expressed HSPs were heated for 30 minutes at 45 °C to 
denature luciferase and (chaperone-assisted) refolding was measured by allowing an 1 hour re-
covery period at 37 °C. Overexpression of the classical V5 tagged chaperones HSPB1, HSPB4 
and HSPB5 increased luciferase refolding compared to cells co-expressing mRFPruby (a non-
chaperone control) (Figure 6c), consistent with previous data (39;43). Overexpression of the 
other HSPB members, including HSPB7, showed no comparable activities on luciferase refold-
ing (Figure 6c). Overexpression of non-tagged HSPB1 and HSPB7 gave similar results com-
pared to the V5-tagged versions (Figure 6d), demonstrating that V5-tagging did not negatively 
influence refolding activity. This suggests that HSPB7 does not act as a classical chaperone at 
least not when firefly luciferase is used as a substrate.
Figure 5. HSPB7 efficacy is reduced in autophagy-deficient ATG5 -/- cells. (A) Wildtype MEF cells 
(ATG5 +/+) were co-transfected with V5-tagged HSPB1, HSPB7 or His-tagged BAG3 together with EGFP-
HttQ74 (9:1 ratio). Cell lysates were analysed by filtertrap binding 48 hours after transfection. (B) Western-
blot analysis shows that BAG3, but not HSPB7, reduces the soluble pool of EGFP-HttQ74. (C) V5-tagged 
HSPB1, HSPB7 or His-tagged BAG3 were co-transfected with EGFP-HttQ74 (9:1 ratio) in MEF cells lacking 
the ATG5 gene (ATG5 -/-). Both BAG3 activity and HSPB7 activity was reduced. (D) Westernblot analysis 
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HSPB7 is not dependent on a functional HSPA machine or activity of 
HSF-1
To explore whether the action of HSPB7 on poly-Q aggregation was dependent on collaboration 
with HSPA members, we initially aimed to down regulate HSPA8 and HSPA1, the endogenously 
expressed HSPA members in HEK293 cells (Hageman and Kampinga, unpublished observa-
tions). However, this turned out to be rather toxic to these cells. We therefore used an indirect 
approach to address this question and co-transfected the HEK293 cells with HSPB7 and EGFP-
HDQ74 with or without BAG1. BAG1 is a nucleotide exchange factor that accelerates the AT-
Pase cycle of HSPA and we previously showed that BAG1 overexpression leads to a negative 
effect on HSPA1A-mediated refolding (44) and hereby also interferes with the effect of HSPB1 
on protein refolding (39). Co-expression of HSPA1A and BAG1 with either cytosolic or nuclear 
luciferase resulted in a decrease in refolding activity (Figure 7a), showing that HSPA mediated 
refolding is affected in both cellular compartments. However, BAG1 overexpression did not sig-
nificantly affect HSPB7 activity on polyQ aggregation (Figure 7b), showing that HSPB7s major 
route of anti-aggregation does not require HSPA activity. To exclude that HSPB7 overexpression 
might induce a general stress response that upregulates other chaperones that in turn ensure 
clearance of poly-Q aggregates, we first measured levels of the stress inducible HSPA1A and 
DNAJB1. HSPB7 overexpression did not lead to a detectable induction of these classical heat-
shock proteins (Figure 7c). In addition, we co-expressed EGFP-HttQ74 with either HSPB5 or 























































































































































Figure 6. HSPB7 is not a canoni-
cal small heat shock protein. (A) 
HEK293 cells were transfected with 
either V5-tagged HSPB5 or HSPB7. 
Cell lysates were separated on a 
sucrose-gradient. Whereas HSPB5 
oligomers can be detected almost 
throughout the  sucrose gradients, in-
dicative a hetero-oligomeric complex 
formation, HSPB7 is found only the 
less dense fractions (mainly mono- 
and dimers). (B) Native page gel 
analysis of either V5-tagged HSPB1 
or HSPB7 expressed in HEK293 cells. 
HSPB1 forms large oligomeric struc-
tures while HSPB7 migrates as a sin-
gle molecular species. (C) Cells were 
co-transfected with firefly luciferase 
and the indicated chaperones (1:9 ra-
tio). Cells were heat-shocked at 43 °C 
for 30 minutes and allowed to recover 
for 1 hour at 37 °C. The percentage 
of reactivated luciferase, relative to 
the un-heated controls is depicted. 
Error bars indicate the SD of three 
independent experiments. (D). To rule 
out that the V5-tag negatively affected 
HSPB1 or HSPB7 activity in relation to 
luciferase refolding, activities of both 
non-tagged and tagged HSPB1 and 
HSPB7 were compared.
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construct which blocks HSF-1 dependent HSP expression. Expression of the dnHSF-1 construct 
effectively blocked the heat shock induced-expression of the HSF-1 inducible HSPA6 protein 
(Figure 7d). In these cells, that can no longer induce a stress response, HSPB7 retained its full 
activity to suppress poly-Q aggregation (Figure 7e). Thus, HSPB7 does not induce the general 
heat shock response and does not require induction of other heat shock proteins through HSF-1 
in order to be functional. 
HSPB7 sequence features in relation to anti-aggregation activity
HSPB7 was originally discovered as a cardiovascular HSPB member (cvHSP) but although 
it is indeed highly expressed in cardiac tissue (45), database analyses revealed that HSPB7 
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Figure 7. HSPB7 does not require a functional HSPA machine, induces no general stress response 
and is not dependent on HSF-1 responsive genes to reduce polyglutamine aggregation. (A) HSPA1A 
was cotransfected with BAG1, cytoplasmic luciferase or nuclear luciferase (4,5:4,5:1 ratio). Cells were heat 
shocked at 43oC for 30 minutes and allowed to recover after which luciferase activity was determined. In 
both compartments, co-expression of BAG1 inhibits the HSPA machine. (B) Co-expression of BAG1 with 
HSPB7 and EGFP-HttQ74 shows that BAG1 mediated inhibition of the HSP70 machine only marginally 
reduced the effect of HSPB7 on preventing polyQ aggregation. (C) HEK293 cells were transfected with 
either mRFPruby, V5-tagged HSPB5 or HSPB7 with (+) or without (-) HA-HttQ43 encoding plasmids. Levels 
of the stress-inducible HSPA1A and DNAJB1 were not altered under these conditions, indicating that none 
of them induced a general stress response. (D) The dominant negative HSF-1 cell line lacks HSF-1 induc-
ible gene expression as can be seen by a failure of these cells to induce the expression of stricktly heat-
inducible HSPA6 within 12 hours after a 30 minutes heat shock at 43 °C. (E) Using either HEK293 cells or 
the dominant negative HSF-1 celline, V5-tagged HSPB5 or HSPB7 were co-transfected with EGFP-HttQ74 
(9:1 ratio). In both cell lines, HSPB7 was found equally effective in suppressing HttQ74 aggregation.
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highest expressed HSPB members in human tissues at the messenger level which suggests a 
general function in cells (Chapter 3). Furthermore, HSPB7 homologs can be found throughout 
vertebrate species (46) (Figure 8a). To test whether HSPB7 from different species are functional 
homologs of the human HSPB7, we co-expressed EGFP-HttQ74 with either human, mouse, fish 
or frog HSPB7 and compared their efficacy on preventing polyQ aggregation in human HEK293 
cells. All HSPB7 species variants were able to suppress polyQ aggregation (Figure 8b), strongly 
suggesting that they are true orthologs of human HSPB7 and that they have a general function 
that is maintained when expressed in cells derived from a different species. 
The main sequence-related feature that makes HSPB7 unique within the HSPB family is the 
presence of a conserved N-terminal serine-rich region of approximately eighteen residues. In 
addition, HSPB7 contains a conserved C-terminal region (C-box) of nine residues. Both these 
sequence features are also conserved in mouse, fish and frog orthologs (Figure 8a). In addi-
tion, we recently found that the N-terminus contains targeting motifs required for HSPB7 to be 
located to nuclear SC35 splicing speckles (Chapter 3). To investigate the role of these features 
on preventing polyQ aggregation, we co-expressed EGFP-HttQ74 with several human HSPB7 
deletion mutants (Figure 8c). Deletion of the serine-rich region, previously shown to be redun-
dant for SC35 speckle association, did not affect the activity of HSPB7 against polyQ aggrega-
tion (Figure 8d). Deletion of the N-terminal domain, which leads to displacement of HSPB7 from 
SC35 speckles, strongly reduced the activity of HSPB7 against polyQ aggregation (Figure 8d). 
Deletion of the nine C-terminal residues of HSPB7 did not affect the activity of HSPB7 against 
polyQ aggregation (Figure 8d). Thus, both the HSPB7-specific serine-rich region and the C-box 
are redundant features not required for preventing polyQ aggregation. A combination of these 
two deletions still resulted in an active HSPB7 mutant protein (data not shown). On the other 
hand, the role of the N-terminus seems indispensable in preventing polyQ aggregation. This 
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Figure 8. HSPB7 activity in pre-
venting polyglutamine aggrega-
tion is evolutionary conserved 
and independent of two conserved 
motifs. (A) Sequence alignment of 
Homo sapiens (Hs), Mus musculus 
(Mm), Danio rerio (Dr) and Xeno-
pus leavis (Xl) HSPB7. (B) Human 
HEK293 cells were co-transfected 
with HSPB7 and EGFP-HttQ74 (9:1 
ratio) from the indicated species. Re-
duction in polyglutamine aggregation 
was analysed by the filtertrap binding 
assay. (C) Schematical overview of 
the HSPB7 topology and the dele-
tion mutants. (D) HEK293 cells were 
co-transfected with EGFP-HDQ74, 
wildtype HSPB7 or the deletion mu-
tants (1:9 ratio). Deletion of the con-
served serine stretch or the C-box 
did not abolish effects of HSPB7 on 
polyglutamine aggregation. Deletion 
of the complete N-terminus did abro-
gate anti-polyglutamine aggregation 
activity.
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could merely reflect the deletion of a substrate interaction domain, as implicated for other small 
HSP proteins (40;47;48), or that SC35 speckle association of the HSPB7 N-terminus has a role 
in preventing polyQ aggregation.
HSPB7 prevents polyQ aggregation in neuronal-like cells
Although the precise mechanism remains to be elucidated, the above data show that HSPB7 
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Figure 9. HSPB7 co-localizes with polyQ aggregates and reduces aggregate formation in neuronal 
cells. (A) NG108 cells were differentiated (see materials and methods) into neuronal cells during a seven 
day period. Cells were transfected after differentiation with EGFP tagged SCA3-Q64. After 48 hours cells 
were fixed with methanol and analysed by confocal microscopy. (B) After differentiation, cells were co-
transfected with EGFP-SCA3-Q64 and V5-HSPB7 encoding plasmids (1:9 ratio). In the low fraction of cells 
expressing HSPB7 that did show aggregates, V5-HSPB7 colocalized with these intranuclear SCA3 aggre-
gates. The number of cells positive for either EGFP-HDQ74 (C) or  SCA3-Q64 (D) inclusions in transfected 
differentiated NG108 cells  overexpressing either HSPB7, V5-HSPB7, HSPB5 or V5-HSPB5 were counted 




is also effective in reducing polyQ aggregation and toxicity in neurons, we first co-transfected 
differentiated NG-108 neuroblastoma x glioma cells with HSPB7 and EGFP-HttQ74 or EGFP-
SCA3Q63. Interestingly, overexpression of polyQ proteins (without NLS) in these cells led to 
an exclusive nuclear accumulation of polyQ aggregates, leaving the cytoplasm almost void of 
polyQ inclusions (Figure 9a), which is entirely different from what was found in HEK293 cells, 
unless we used NLS-mediated targeting. HSPB7 showed co-localization with the nuclear polyQ 
aggregates (Figure 9b), Since transfection efficiencies were very low, we could not use bio-
chemical endpoints to test whether HSPB7 reduced the process of aggregation also in these 
NG108 cells. Therefore, we calculated the fraction of green, EGFP-HttQ74 or EGFP-SCA3Q63 
expressing cells with visible inclusions (Figure 9c,d). Clearly, also in differentiated NG-108 cells 
Figure 10. HSPB7 reduces polyQ induced toxicity in cells and in vivo. PolyQ induced cellular toxicity 
was analysed using a HEK293 cell line containing a tetracycline inducible EGFP-HttQ119 construct (53) that 
stably expressed either non-tagged HSPB5 or HSPB7. (A) Addition of tetracycline to induce the expression 
of EGFP-HttQ119 (panel A, upper lane) (B) Long term toxicity of polyQ expression was evaluated using the 
colony formation assay showing reduced colony formation (within two weeks) upon poly-Q expression. (C) 
Quantitative analysis of colony formation reveals that expression of EGFP-HttQ119 alone or together with 
HSPB5 results in a major reduction of colonies. Co-expression of HSPB7 results in a significant protection 
against polyQ toxicity. (D) The Drosophila SCA3 model (32) was used to evaluate the effect of HSPB7 
expression on eye-degeneration. HSPB7 transgenic flies were generated and expression of HSPB7 alone 
caused no phenotypic changes and these flies had normal eye morphology (D1). Expression of HSPB7 was 
tested by crossing the Actin-GAL4 driver fly with the HSPB7 transgenic fly (D1, bottom right insert). Expres-
sion of SCA3trQ78 resulted in a visible degeneration (D2). A mild reduction upon co-expression of HSPB7 
on SCA3trQ78 induced eye degeneration was observed, but this effect was not statistically significant (data 
not shown & D3). (E) By analysing positive phototaxis, a significant reduction in blindness could be observed 
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HSPB7 (both V5- and non-tagged) effectively reduced polyQ aggregation, while overexpression 
of HSPB5 had only a minor effect.
HSPB7 reduces polyQ related toxicity
We next analyzed if HSPB7, in addition to reducing polyQ aggregation, could also reduce 
polyQ-induced cytotoxicity. Hereto, we used a HEK293 cell line containing a tetracycline induc-
ible EGFP-HttQ119 construct. These cells were next used to generate stable lines constitutively 
expressing either non-tagged HSPB5 or non-tagged HSPB7 (Figure 10a). Expression of EGFP-
HttQ119 was subsequently induced by addition of 1 µg/ml tetracycline (Figure 10a) and long 
term toxicity was evaluated using colony formation (i.e the ability of individual cells express-
ing polyQ proteins to form colonies containing at least 50 cells within 2 weeks). Expression of 
EGFP-HttQ119 severely affected colony-forming ability, indicating polyQ-induced cytotoxicity 
(Figure 10b,c). While co-expression of HSPB5 did not significantly protect against cytotoxicity, 
co-expression of HSPB7 led to a significant reduction in polyQ mediated cytotoxicity (Figure 
10b,c). HSPB7 expression alone did not affect cell growth or colony formation (data not shown). 
Thus, HSPB7 is not only able to both reduce polyQ aggregate formation in cells but also reduces 
polyQ induced cytotoxicity. 
To test if HSPB7 can also prevent polyQ-induced neuronal toxicity in vivo, we targeted HSPB7 
overexpression in the compound eyes of the Drosophila SCA3 model (32). This fly model is 
characterized by continuous expression of a truncated polyQ-expanded SCA3-gene (SCA3-
trQ78) in the compound eyes, resulting in neurodegeneration and blindness. Overexpression 
of polyQ expanded SCA3 resulted in visible eye degeneration (Figure 10d) and loss of posi-
tive phototaxis, a measure for blindness (Figure 10e). HSPB7 transgenic flies showed normal 
eye-morphology and phototaxis (Figure 10d,e). Although expression of HSPB7 in the SCA3 
transgenic flies did not result in statistically significant amelioration of the SCA-3 induced eye-
degeneration (data not shown), a significant improvement in positive phototaxis was seen (Fig-
ure 10d,e). So, HSPB7 is not only functional in preventing polyQ aggregation in cells in vitro, but 
is also able to reduce polyQ-induced toxicity in vivo
Discussion
In this work, we have compared the various members for their ability to prevent polyQ aggrega-
tion and identified, HSPB7 as the most active member. Its mode of action was demonstrated to 
be of a non-canonical nature: although HSPB7 was in part dependent on autophagy, it functions 
independently of proteasomal degradation. Furthermore, HSPB7 did not form high-molecular 
weight complexes like HSPB1 and HSPB5, which are implicated as being important for their 
chaperone activity. In agreement with this, HSPB7 was unable to chaperone heat-denatured lu-
ciferase, a well known substrate for both HSPB1 and HSPB5. Although the precise mechanisms 
remains to be elucidated, HSPB7-like activities are evolutionary conserved and also prevent 
aggregate formation in neuronal-like cells and even reduce cytotoxicity and neuronal toxicity in 
cells and in vivo respectively, making it an excellent candidate for future therapeutic strategies.
HSPB members show diversity in cellular activity 
By screening the HSPB family for activity against amyloid fibril formation of polyQ proteins, 
a clear difference in their respective capacities to handle this substrate was found. Whereas 
the classical, well-studied HSPB1 and HSPB5 assist in refolding of heat denatured luciferase, 
and show substantial activity against aggregation of diverse other substrates (27;49;50), they 
were merely ineffective in preventing polyQ aggregation (12) (this study). Strikingly, HSPB9 
and especially HSPB7 were most effective in reducing polyQ aggregation, but did not sup-
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port refolding of heat unfolded luciferase. This set of data suggests at least two points. Firstly, 
diverse HSPB members can act on different substrates consistent with a rather promiscuous 
substrate recognition ability. Secondly, the effectiveness of the various members to handle (the 
same) substrates differs. This could mean that binding of a certain substrate to one HSPB is 
more efficient for its further processing (refolding, proteasomal degradation, autophagosomal 
routing etc.) than binding to another HSPB member. The latter may occur via additional inter-
action partners of the diverse HSPB members and or via differential substrate binding affinity 
e.g. impaired hand-over to HSPA members. Whereas relatively lower substrate affinity (e.g. 
HSPB1) could favor transfer to HSPA members and subsequent substrate folding (luciferase), 
tentative stronger substrate affinities (or other non-HSPA dependent mechanisms: e.g. HSPB7) 
may avoid the danger of transfer to HSPA members for non-refoldable substrates like polyQ 
that are poorly handled by the proteasome. Whereas such a model requires further biochemical 
evidence, it is supported by several other observations. Those HSPB members that function in 
stimulating luciferase refolding depend on a functional HSPA machine (39;this study) and be-
have like classical dynamic oligomers as has been described in cell free experiments (23;51). 
Such members are usually poor suppressors of polyQ aggregation (12;this study). Inversely, the 
effect of HSPB7 on polyQ aggregation does not require a functional HSPA machine (this study) 
and a mere independence of the HSPA machine in preventing polyQ aggregation was recently 
also found for strong suppressors in the family of DNAJ proteins (9;52) that also do not support 
protein refolding reactions (53).
Clearly HSPB7 is not the only non-canonical member of the HSPB family, Also HSPB8 does not 
form the classical oligomeric complexes in cells but rather forms a stoichiometric complex with 
BAG3 (2:1). This complex induces autophagy (15) and inhibits protein synthesis in a HSP70-
independent but eIF2a-dependent manner (16). Hereby it also can lead to reduced polyQ ag-
gregates, although this mechanism seems less effective in handling long polyQ expansions 
(this study). Although HSPB7 in part also depends on active autophagy, its mechanism of action 
seems distinct from the BAG3/HSPB8 complex as its activity does not seems to affect soluble 
protein levels, meaning that unlike the BAG3/HSPB8 it does not act on protein synthesis.
Oligomerization of HSPB members and anti-aggregation
One striking distinction between the non-canonical polyQ chaperoning HSPB proteins (HSPB6, 
HSPB7, HSPB8) and the classical HSPB proteins (HSPB1, HSPB5), seems to be the finding 
that they do not exist as large oligomers within living cells. While active chaperone activity of 
HSPB1 towards unfolded proteins is dependent on oligomeric dynamics(51;54), HSPB7 was 
found to exist as either mono- or dimeric sizes. Also HSPB6 and HSPB8, active in reducing 
HA-HttQ43 aggregation, are reported to mainly exist as dimers or small oligomers respectively 
(55;56). 
Why would HSPB7, that can reduce amyloid fibril formation of polyQ containing proteins, not also 
support refolding of heat-denatured luciferase, which forms amorphous aggregates. Success-
ful chaperoning of this specific substrate rather seems to require shuttling between dimers and 
large oligomers (39). As we were unable to detect clear degradation-related effect on reducing 
polyQ aggregation by HSPB7 and in addition a lack of requirement of HSPA and other stress-
induced chaperones, we propose that HSPB7 might function by transiently shielding the polyQ 
stretch and effectively preventing polyQ-oligomer formation and halting the process of inclusion 
formation. These chaperone-polyQ oligomers next may be (slowly) cleared by autophagy, which 
could explain why HSPB7 is less efficient in ATG5 -/- cell defective in macroautophagy In this 
way, seed formation for further aggregation is reduced and other cellular degradation pathways 
are allowed a larger time-window to clear the aggregation-prone substrate without the require-
ment of boosting either proteasomal or autophagic clearance. A similar mode of action has been 
suggested for HSPB5 in preventing nucleation of amyloid fibril forming substrate in vitro (57;58), 
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a process leading to aggregate formation. Yet, HSPB5 seems unable to act in reducing polyQ 
aggregation, again suggesting specificity in substrate chaperoning. An alternative hypothesis 
could be that HSPB7 somehow has indirect effects on poly-Q aggregation via an effect on RNA 
metabolism. In chapter 3 we showed that HSPB7 is associated with SC35 speckles that play 
a role in RNA splicing and processing. By acting as a possible RNA chaperone, HSPB7 may 
effectively decrease aggregation of triplet expanded RNA species hereby maintaining cellular 
homeostasis and the ability of reducing the burden of unfolded peptides via constitutively active 
protein quality control pathways.
HSPB7 is able to reduce polyQ aggregation and toxicity in several models used here, which 
are all associates with an overwhelming induction of polyQ expression in a very short time. 
As negative effects of expanded polyQ protein expression in patients accumulates over many 
years, HSPB7 activity in vitro might translate in such situations in a highly effective strategy to 
handle polyQ fibril formation. Taken together, HSPB proteins in general show a diverse and of-
ten specific chaperone activity towards proteins tending to form either amorphous or amyloidal 
aggregates, with sometimes diverse outcomes on cellular survival. The comparative study pre-
sented here forms a beginning in our understanding on substrate-specificity of HSPB proteins 
and differences in their mode of action. Further comparative studies using different substrate 
proteins are embraced to clarify the role of substrate in relation to HSPB chaperone activity.
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